Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2022 | 2903 | 0.680 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2006 | 20 | 0.580 |
Why?
|
| Graft Rejection | 5 | 2023 | 1065 | 0.430 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 318 | 0.420 |
Why?
|
| Heart Transplantation | 3 | 2023 | 705 | 0.400 |
Why?
|
| Receptors, Complement 3d | 2 | 2006 | 14 | 0.360 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2008 | 12 | 0.340 |
Why?
|
| Skull Neoplasms | 1 | 2008 | 30 | 0.330 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 81 | 0.330 |
Why?
|
| Receptor, ErbB-2 | 5 | 2022 | 223 | 0.320 |
Why?
|
| Lymph Nodes | 3 | 2019 | 533 | 0.320 |
Why?
|
| Temporal Bone | 1 | 2008 | 66 | 0.320 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 113 | 0.310 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 157 | 0.290 |
Why?
|
| Skin Transplantation | 4 | 2022 | 172 | 0.280 |
Why?
|
| Isoantigens | 2 | 2023 | 66 | 0.270 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 2262 | 0.260 |
Why?
|
| Sarcoma | 1 | 2006 | 215 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2023 | 425 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1313 | 0.200 |
Why?
|
| Tomography, Optical | 1 | 2019 | 9 | 0.180 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 15 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2438 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2019 | 22 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2022 | 265 | 0.170 |
Why?
|
| Optical Imaging | 1 | 2019 | 48 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 486 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 162 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 2360 | 0.140 |
Why?
|
| Mice | 12 | 2023 | 11352 | 0.120 |
Why?
|
| Endotoxemia | 1 | 2014 | 18 | 0.120 |
Why?
|
| Endotoxins | 1 | 2014 | 36 | 0.120 |
Why?
|
| Female | 14 | 2022 | 44532 | 0.120 |
Why?
|
| Hypothalamus | 1 | 2014 | 79 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 1565 | 0.120 |
Why?
|
| Frontal Lobe | 1 | 2014 | 130 | 0.110 |
Why?
|
| HMGA2 Protein | 1 | 2013 | 14 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 124 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2023 | 996 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 123 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 1753 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 167 | 0.100 |
Why?
|
| Animals | 14 | 2023 | 26582 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 144 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2022 | 337 | 0.100 |
Why?
|
| Humans | 17 | 2022 | 86643 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1197 | 0.100 |
Why?
|
| Transplantation Tolerance | 2 | 2023 | 130 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 251 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 169 | 0.090 |
Why?
|
| Hippocampus | 1 | 2014 | 442 | 0.090 |
Why?
|
| Depression | 1 | 2014 | 473 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3362 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 164 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 645 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1578 | 0.080 |
Why?
|
| Cadherins | 1 | 2009 | 151 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 920 | 0.080 |
Why?
|
| Hematopoietic System | 1 | 2008 | 13 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 466 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2022 | 1047 | 0.080 |
Why?
|
| Aged | 4 | 2022 | 18415 | 0.080 |
Why?
|
| fas Receptor | 1 | 2008 | 75 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2010 | 409 | 0.070 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 39 | 0.070 |
Why?
|
| Muromonab-CD3 | 3 | 1995 | 69 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 64 | 0.070 |
Why?
|
| Immunosuppressive Agents | 3 | 1995 | 977 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 267 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2022 | 3092 | 0.060 |
Why?
|
| Liver | 1 | 2008 | 1230 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2023 | 203 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2022 | 109 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 7993 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2010 | 315 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 136 | 0.050 |
Why?
|
| Rats | 3 | 2019 | 3990 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 736 | 0.050 |
Why?
|
| Antigens | 1 | 2022 | 228 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1464 | 0.050 |
Why?
|
| Middle Aged | 4 | 2022 | 25028 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 2426 | 0.050 |
Why?
|
| Adult | 4 | 2022 | 25648 | 0.050 |
Why?
|
| Graft Survival | 2 | 2022 | 884 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2020 | 68 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 250 | 0.050 |
Why?
|
| Peptides | 1 | 2023 | 639 | 0.050 |
Why?
|
| Taxoids | 1 | 2020 | 129 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 299 | 0.040 |
Why?
|
| Scattering, Radiation | 1 | 2019 | 114 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 31 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 295 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 188 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2019 | 305 | 0.040 |
Why?
|
| Risk Factors | 1 | 2009 | 5417 | 0.040 |
Why?
|
| CD3 Complex | 2 | 1995 | 135 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 555 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 859 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 1056 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 1204 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 3241 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1373 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2601 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1513 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1995 | 13 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1163 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 1995 | 52 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 1995 | 75 | 0.030 |
Why?
|
| Guanidines | 1 | 1994 | 31 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1995 | 106 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 36 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 88 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 87 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 78 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1994 | 171 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3679 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 557 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 54 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 297 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 123 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 289 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1995 | 428 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 504 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 91 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 93 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2012 | 303 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 220 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 5976 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 813 | 0.020 |
Why?
|
| Male | 4 | 2010 | 40965 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 712 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 217 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 357 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 567 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2010 | 152 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 752 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 8489 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1540 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1981 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 1995 | 728 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 229 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 370 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1531 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 29 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2006 | 37 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 48 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 689 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 135 | 0.020 |
Why?
|
| Mice, Inbred DBA | 2 | 1995 | 148 | 0.020 |
Why?
|
| Cricetinae | 2 | 1995 | 560 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 559 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1683 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 3968 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2232 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1995 | 44 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 104 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1995 | 40 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1995 | 131 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1995 | 109 | 0.010 |
Why?
|
| Abatacept | 1 | 1995 | 83 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 111 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 95 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1995 | 85 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1995 | 81 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 1995 | 187 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1995 | 135 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1995 | 141 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1995 | 114 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 646 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1994 | 97 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 154 | 0.010 |
Why?
|
| Immunization | 1 | 1994 | 158 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 252 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1994 | 249 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 376 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1995 | 458 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 456 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2062 | 0.010 |
Why?
|
| Cytokines | 1 | 1995 | 776 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2330 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 3030 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 1195 | 0.010 |
Why?
|